RU2482858C1 - Method for drug-free correction of idiopathic asthenozoospermia - Google Patents
Method for drug-free correction of idiopathic asthenozoospermia Download PDFInfo
- Publication number
- RU2482858C1 RU2482858C1 RU2011142584/15A RU2011142584A RU2482858C1 RU 2482858 C1 RU2482858 C1 RU 2482858C1 RU 2011142584/15 A RU2011142584/15 A RU 2011142584/15A RU 2011142584 A RU2011142584 A RU 2011142584A RU 2482858 C1 RU2482858 C1 RU 2482858C1
- Authority
- RU
- Russia
- Prior art keywords
- points
- area
- drug
- point
- projection
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 14
- 206010067162 Asthenospermia Diseases 0.000 title claims abstract description 5
- 208000007799 Asthenozoospermia Diseases 0.000 title claims abstract description 5
- 210000003689 pubic bone Anatomy 0.000 claims abstract description 6
- 210000001015 abdomen Anatomy 0.000 claims abstract description 3
- 230000019612 pigmentation Effects 0.000 claims abstract description 3
- 241000545744 Hirudinea Species 0.000 claims description 9
- 210000000954 sacrococcygeal region Anatomy 0.000 claims description 3
- 230000000144 pharmacologic effect Effects 0.000 claims description 2
- 210000004392 genitalia Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 4
- 241000237902 Hirudo medicinalis Species 0.000 abstract description 3
- 230000035558 fertility Effects 0.000 abstract description 2
- 210000003899 penis Anatomy 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 229940094892 gonadotropins Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000005184 men's health Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000017497 prostate disease Diseases 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 230000019100 sperm motility Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Область применения: предлагаемое изобретение относится к области медицины, а именно к урологии.Scope: the present invention relates to medicine, namely to urology.
Уровень техникиState of the art
АналогиAnalogs
1. Применение гонадотропинов. Эффективность в течение последних десятилетий подвергнута сомнению, целесообразность применения метода [1, 2, 3].1. The use of gonadotropins. Efficiency over the past decades has been questioned, the appropriateness of applying the method [1, 2, 3].
2. Лечение андрогенами. Метод относится к антифертильным, его применение остается дискутабельным [1].2. Treatment with androgens. The method relates to antifertil, its use remains debatable [1].
3. Антиэстрогены и ингибиторы ароматазы. Отсутствуют убедительные данные по эффективности метода [1].3. Antiestrogens and aromatase inhibitors. No convincing data on the effectiveness of the method [1].
4. Применение калликреина не нашло подтверждения при многоцентровых исследованиях [1].4. The use of kallikrein was not confirmed by multicenter studies [1].
5. Использование пентоксифилина, доказана эффективность при применении в циклах вспомогательных репродуктивных технологий in vitro [4].5. The use of pentoxifyline, proven to be effective when used in cycles of assisted reproductive technologies in vitro [4].
6. Применение α-блокаторов, метод находится еще на стадии статистической разработки, контролируемых клинических испытаний [1].6. The use of α-blockers, the method is still at the stage of statistical development, controlled clinical trials [1].
7. Использование антиоксидантов аскорбиновой кислоты, глутатиона, витамина Е [5, 6, 7, 8]. Методики применения различаются у разных авторов, носят описательный характер, четко не определены критерии назначения и длительности применения препаратов, имеют несколько эмпирический характер.7. The use of antioxidants of ascorbic acid, glutathione, vitamin E [5, 6, 7, 8]. Methods of application differ among different authors, are descriptive in nature, the criteria for the appointment and duration of the use of drugs are not clearly defined, they are somewhat empirical.
ПрототипPrototype
Прототипом предложенного метода является методика, описанная Каменевым О.Ю., Барановским А.Ю. [9], для лечения заболеваний предстательной железы. Однако авторы не использовали его для восстановления качественных показателей эякулята.The prototype of the proposed method is the technique described by Kamenev O.Yu., Baranovsky A.Yu. [9], for the treatment of prostate diseases. However, the authors did not use it to restore the quality indicators of the ejaculate.
Сущность изобретения.SUMMARY OF THE INVENTION
Цель изобретения заключается в разработке способа немедикаментозной коррекции идиопатической астенозооспермии путем улучшения микроциркуляции органов малого таза и мошонки при воздействии на специфические отделы мужского организма медицинскими пиявками (Hirudo medicinalis).The purpose of the invention is to develop a method for non-pharmacological correction of idiopathic asthenozoospermia by improving the microcirculation of the pelvic organs and scrotum when exposed to specific sections of the male body with medical leeches (Hirudo medicinalis).
Метод осуществляется следующим способом.The method is carried out in the following way.
Приставки пиявок производят через день в следующих последовательно чередующихся друг за другом зонах:Leech prefixes are produced every other day in the following zones, successively alternating one after another:
1. Лонная область - точка (1) по средней линии над лонной костью, точка (2) у основания полового члена, две точки (3; 4), параллельные на пересечении линии боковой линии живота и лонной кости с обеих сторон. Одновременно ставят по 1 пиявке на каждую точку 4 раза через день.1. The pubic region - a point (1) along the midline above the pubic bone, a point (2) at the base of the penis, two points (3; 4) parallel to the intersection of the lateral line of the abdomen and pubic bone on both sides. At the same time put 1 leech on each point 4 times every other day.
2. Перианальная зона - точки 5, 6, 7, 8, соответствующие III, VI, IX, XII часам перианальной зоны, отступая от зоны пигментации на 1-2 см. Одновременно ставят по 1 пиявке на каждую точку 4 раза через день.2. Perianal zone - points 5, 6, 7, 8, corresponding to the III, VI, IX, XII hours of the perianal zone, departing from the pigmentation zone by 1-2 cm. At the same time put 1 leech on each point 4 times every other day.
3. Крестцовая область - точки 9, 10, 11, 12, расположенные по проекции углов крестца. Одновременно ставят по 1 пиявке на каждую точку 4 раза через день.3. Sacral region - points 9, 10, 11, 12, located on the projection of the corners of the sacrum. At the same time put 1 leech on each point 4 times every other day.
4. Копчиковая область - точки 13, 14, 15, 16, соответствующие проекции копчика. Одновременно ставят по 1 пиявке на каждую точку 4 раза через день.4. Coccygeal region - points 13, 14, 15, 16, corresponding to the projection of the coccyx. At the same time put 1 leech on each point 4 times every other day.
Пример IExample I
Виниченко Сергей Ильич, 12.05.74 г.р. При обследовании выявлена идиопатическая астенозооспермия - сперматозоиды категории А+Б (по классификации ВОЗ, 1999) - 35% (первый анализ), 37% (второй анализ). Проведен курс гирудотерапии по предложенной схеме. Учитывая, что лечение медикаментозными и другими методами могло быть безболезненно отложено по причине длительного оперативного лечения супруги, проведена монотерапия с применением Hirudo medicinalis. По окончанию предложенного курса лечения (через 2-3 недели) показатели спермограммы по подвижности сперматозоидов (категория А+Б) - 49% (первый анализ), 54% (второй анализ).Vinichenko Sergey Ilyich, born 12.05.74 An examination revealed idiopathic asthenozoospermia - spermatozoa of category A + B (according to the WHO classification, 1999) - 35% (first analysis), 37% (second analysis). A course of hirudotherapy according to the proposed scheme. Considering that treatment with medical and other methods could be postponed painlessly due to prolonged surgical treatment of the spouse, monotherapy with Hirudo medicinalis was performed. At the end of the proposed course of treatment (after 2-3 weeks), spermogram indicators for sperm motility (category A + B) - 49% (first analysis), 54% (second analysis).
Пример IIExample II
Казанский Денис Сергеевич, 26.06.1982 г.р. При обследовании выявлена идиопатическая астенозооспермия - сперматозоиды категории А+Б (по классификации ВОЗ, 1999) - 37% (первый анализ), 32% (второй анализ).Kazan Denis Sergeevich, born June 26, 1982 An examination revealed idiopathic asthenozoospermia - spermatozoa of category A + B (according to the WHO classification, 1999) - 37% (first analysis), 32% (second analysis).
Проведен курс гирудотерапии по предложенной схеме. Учитывая, что пациент проходит лечение в объеме подготовки к беременности в браке, от медикаментозных и от других методов коррекции решено отказаться, проведена монотерапия с применением Hirudo medicinalis. По окончанию предложенного курса лечения (через 2-3 недели) показатели спермограммы по подвижности сперматозоидов (категория А+Б) - 47% (первый анализ), 51% (второй анализ).A course of hirudotherapy according to the proposed scheme. Given that the patient is undergoing treatment in the amount of preparation for a married pregnancy, it was decided to abandon the medication and other correction methods, monotherapy was performed using Hirudo medicinalis. At the end of the proposed course of treatment (after 2-3 weeks), spermogram indicators for sperm motility (category A + B) - 47% (first analysis), 51% (second analysis).
Таким образом, способ позволяет достоверно улучшить кинезиограмму сперматозоидов и тем самым повысить фертильность в супружеских парах.Thus, the method allows to significantly improve the kinesiogram of sperm and thereby increase fertility in couples.
Источники информации Information sources
1. Нишлаг Э., Бере Г.М. Андрология. Мужское здоровье и дисфункция репродуктивной системы [Текст] / Под редакцией Э.Нишлага. - ООО «Медицинское информационное агенство», 2005. - 554 с.1. Nishlag E., Bere G.M. Andrology. Men's health and reproductive system dysfunction [Text] / Edited by E. Nishlag. - Medical Information Agency LLC, 2005. - 554 p.
2. Bals-Pratsch M, Knuth UA, Honigl W, Klein HM, Bergmann M, Neschlag E. Pulsatile GnRH-terapi in oligozoospermic men does not improve seminal parameters despite decreased FSH levels. Clin Endocrinol (Oxf). 1989 May; 30(50): 549-60.2. Bals-Pratsch M, Knuth UA, Honigl W, Klein HM, Bergmann M, Neschlag E. Pulsatile GnRH-terapi in oligozoospermic men does not improve seminal parameters despite decreased FSH levels. Clin Endocrinol (Oxf). 1989 May; 30 (50): 549-60.
3. Clark R.V, Sherins R.J. Treatment of men with idiopathic oligozoospermic infertility using the aromatase inhibitor, testolactoce. Results of a doubleblinded, randomized, placebo-controlled trial with crosover. J Androl. 1989 May-Jun; 10(3): 240-7.3. Clark R.V., Sherins R.J. Treatment of men with idiopathic oligozoospermic infertility using the aromatase inhibitor, testolactoce. Results of a doubleblinded, randomized, placebo-controlled trial with crosover. J Androl. 1989 May-Jun; 10 (3): 240-7.
4. Tournaye H, Devroey P, Camus M., Van Linden M, Fanssens R, Van Steirteghem A. Use of pentoxiflylline in assisted reproductive technology. Hum Reprod. 1995 Oct; 10 Suppl 1: 72-9.4. Tournaye H, Devroey P, Camus M., Van Linden M, Fanssens R, Van Steirteghem A. Use of pentoxiflylline in assisted reproductive technology. Hum Reprod. 1995 Oct; 10 Suppl 1: 72-9.
5. Аляев Ю.Г., Григорян В.А., Чалый М.Е., Нарушения половой и репродуктивной функции у мужчин. [Текст] / Ю.Г.Аляев. - М.: Литтерра, 2006. - 188 с.5. Alyaev Yu.G., Grigoryan VA, Chaly ME, Violations of sexual and reproductive function in men. [Text] / Yu.G. Alyaev. - M .: Litterra, 2006 .-- 188 p.
6. Dawson E.B., Harris W.A., Teter M.C., Powell L.C. Effect of ascorbic acid supplementation on the sperm gualiti of smokers. Fertil Steril. 1992 Nov; 58(5): 1034-9.6. Dawson E. B., Harris W. A., Teter M. C., Powell L. C. Effect of ascorbic acid supplementation on the sperm gualiti of smokers. Fertil Steril. 1992 Nov; 58 (5): 1034-9.
7. Ochsendorf F.R. Infections in the male genital tract and reactiv oxygen species. Hum Update. 1999 Sep-Oct; 5(5): 399-420.7. Ochsendorf F.R. Infections in the male genital tract and reactiv oxygen species. Hum Update. 1999 Sep-Oct; 5 (5): 399-420.
8. Suleiman S.A., Ali М.Е., Zaki Z.M., el-Malik E.M., Nasr M.A. Lipid peroxidation and human sperm motility: protective role of vitamin E. J. Androl. 1996 Sep-Oct; 17(5): 530-7.8. Suleiman S.A., Ali M.E., Zaki Z.M., el-Malik E.M., Nasr M.A. Lipid peroxidation and human sperm motility: protective role of vitamin E. J. Androl. 1996 Sep-Oct; 17 (5): 530-7.
9. Каменев О.Ю., Барановский А.Ю. Лечение пиявками: теория и практика гирудотерапии: Руководство для врачей. - СПб: ИГ «Весь», 2006. - 304 с.: ил.9. Kamenev O.Yu., Baranovsky A.Yu. Leech Treatment: Theory and Practice of Hirudotherapy: A Guide for Physicians. - St. Petersburg: IG "Ves", 2006. - 304 p.: Ill.
10. Руководство ВОЗ по лабораторному исследованию эякулята человека и взаимодействия сперматозоидов с цервикальной слизью. 4-е издание - М., МедПресс, 2001. - 144 с.10. WHO guidelines for laboratory testing of human ejaculate and the interaction of sperm with cervical mucus. 4th edition - M., MedPress, 2001 .-- 144 p.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2011142584/15A RU2482858C1 (en) | 2011-10-20 | 2011-10-20 | Method for drug-free correction of idiopathic asthenozoospermia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2011142584/15A RU2482858C1 (en) | 2011-10-20 | 2011-10-20 | Method for drug-free correction of idiopathic asthenozoospermia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2011142584A RU2011142584A (en) | 2013-04-27 |
| RU2482858C1 true RU2482858C1 (en) | 2013-05-27 |
Family
ID=48791814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011142584/15A RU2482858C1 (en) | 2011-10-20 | 2011-10-20 | Method for drug-free correction of idiopathic asthenozoospermia |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU2482858C1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2000117275A (en) * | 1997-12-01 | 2002-07-20 | Сигма-Тау Хелтсайенс С.П.А. | COMPOSITIONS AND METHODS FOR INCREASING CONCENTRATION AND / OR MOBILITY OF Spermatozoa in PEOPLE |
| US20030008921A1 (en) * | 1997-12-01 | 2003-01-09 | Sigma-Tau Healthscience S.P.A. | Medicament and therapeutical method for treating idiopathic asthenozoospermia |
-
2011
- 2011-10-20 RU RU2011142584/15A patent/RU2482858C1/en not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2000117275A (en) * | 1997-12-01 | 2002-07-20 | Сигма-Тау Хелтсайенс С.П.А. | COMPOSITIONS AND METHODS FOR INCREASING CONCENTRATION AND / OR MOBILITY OF Spermatozoa in PEOPLE |
| US20030008921A1 (en) * | 1997-12-01 | 2003-01-09 | Sigma-Tau Healthscience S.P.A. | Medicament and therapeutical method for treating idiopathic asthenozoospermia |
Non-Patent Citations (3)
| Title |
|---|
| VAFA M.R. et al. Coenzyme Q10 improves seminal oxidative defense but does not affect, on semen parameters in idiopathic oligoasthenoteratozoospermia: a randomized double-blind, placebo controlled trial // J Endocrinol Invest. 2011 Sep; 34(8):224-8. * |
| ВАСИЛЕВСКАЯ С.Е. и др. «Роль комбинации тестостерона ундеканоата с тамоксифена цитратом в лечении идиопатической олигозооспермии» // Проблемы репродукции, 3-1999, с.41-42. * |
| ВАСИЛЕВСКАЯ С.Е. и др. «Роль комбинации тестостерона ундеканоата с тамоксифена цитратом в лечении идиопатической олигозооспермии» // Проблемы репродукции, 3-1999, с.41-42. VAFA M.R. et al. Coenzyme Q10 improves seminal oxidative defense but does not affect, on semen parameters in idiopathic oligoasthenoteratozoospermia: a randomized double-blind, placebo controlled trial // J Endocrinol Invest. 2011 Sep; 34(8):224-8. * |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2011142584A (en) | 2013-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jannini et al. | Treatment of sexual dysfunctions secondary to male infertility with sildenafil citrate | |
| Rochlitz | Clinical study of cats injured and killed in road traffic accidents in Cambridgeshire | |
| ES2831673T3 (en) | Stimulator of genital, sexual and reproductive function | |
| RU2482858C1 (en) | Method for drug-free correction of idiopathic asthenozoospermia | |
| Brennan et al. | Gynaecological care after stem cell transplant: an overview | |
| Sönmez et al. | Etiological factors and management in priapism patients and attitude of emergency physicians | |
| Devi et al. | “Alternative medicine”—a right choice for male infertility management | |
| ES2707386T3 (en) | Composition for the treatment of HIV or AIDS | |
| RU2517061C1 (en) | Method of treating male sterility caused by autoimmune response to sperm cells | |
| RU2101017C1 (en) | Method to treat male infertility | |
| MX2022009081A (en) | Cellular uptake. | |
| ياسر الوتار et al. | Effect of mobile phone usage on semen analysis in infertile men | |
| RU2757455C1 (en) | Method for the treatment of idiopathic male infertility in the form of oligospermia, oligozoospermia and/or asthenozoospermia | |
| Conners et al. | PRESERVATION OF NORMAL CONCENTRATIONS OF PITUITARY GONADOTROPINS DESPITE ACHIEVEMENT OF NORMAL SERUM TESTOTERONE LEVELS IN HYPOGONADAL MEN TREATED WITH A 4.5% NASAL TESTOSTERONE GEL: MP89-06 | |
| BRPI0517950A (en) | use of androgens to reduce the likelihood of acquiring or to treat skin aging | |
| Markandeya | Postpartum Complications in Buffaloes-A Review. | |
| WO2013160914A1 (en) | Novel synergistic composition comprising of a carotenoid, serm and an amino acid derivative thereof | |
| Kumar et al. | Management of pre-cervical uterine torsion in a buffalo | |
| Walia et al. | Therapeutic efficacy of AV/UTL/17 in cases of postpartum gynaecological disorders in cows: a field study | |
| RU2008150987A (en) | METHOD FOR TREATING LONG TUBULAR BONE FRACTURES | |
| Yang et al. | 273 Efficacy of Dapoxetine in the Treatment of Premature Ejaculation Patients Who Previously Failed Sertraline Therapy | |
| Bhardwaj et al. | Management of Dystocia Due to Fetal Ascites in Boer Goat: A Case Report | |
| Glezerman | Artificial homologous insemination | |
| Berköz et al. | Effect of postmenopausal strontium ranelate treatment on oxidative stress in rat skin tissue. | |
| Patel et al. | A comparative study of scalpel versus no scalpel vasectomy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20141021 |